Clinical Application of Drug Delivery Systems in Cancer Chemotherapy: Review of the Efficacy and Side Effects of Approved Drugs
Open accessThe DOI matches its Crossref record.
Abstract
In recent years, drug delivery systems (DDS) have been developed, along with anticancer agents for those systems based on the concept of achieving a better clinical response and tolerability. Several clinical trials have shown that these drugs have better clinical effects in the treatment of many cancers, leading to their expanded indications. Liposomal doxorubicin is one DDS agent used to treat AIDS-related Kaposi's sarcoma and ovarian cancer in Japan. In addition to those two indications, the Food and Drug Administration (FDA) approved this drug for the treatment of multiple myeloma in 2007. Another DDS agent approved in Japan is nanoparticle albumin-bound paclitaxel, which has been used in the treatment of breast cancer. Most recently, this drug has been approved for the treatment of non-small cell lung cancer in the U.S.A. Although these DDS agents appear to be less toxic than conventional drugs, DDS-specific side effects such as various skin reactions, hypersensitivity reaction, and peripheral neuropathy sometimes occur. Therefore, medical staff must understand DDS anticancer agents fully, including characteristic side effects, to achieve the desired clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization
Sun, Q., Zhou, Z., Qiu, N., & Shen, Y. (2017) · Advanced Materials · doi:10.1002/adma.201606628 · Cited by 1,058
Yusuf, A., Almotairy, A. R. Z., Henidi, H., Alshehri, O. Y., & Aldughaim, M. S. (2023) · Polymers · doi:10.3390/polym15071596 · Cited by 914
Advances in Biomaterials for Drug Delivery
Fenton, O. S., Olafson, K. N., Pillai, P. S., Mitchell, M. J., & Langer, R. (2018) · Advanced Materials · doi:10.1002/adma.201705328 · Cited by 855
Xia, Q., Zhang, Y., Li, Z., Hou, X., & Feng, N. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.01.011 · Cited by 665
Unraveling the mysteries of serum albumin—more than just a serum protein
Merlot, A. M., Kalinowski, D. S., & Richardson, D. R. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00299 · Cited by 641
Nanoparticles and nanofibers for topical drug delivery
Goyal, R., Macri, L. K., Kaplan, H. M., & Kohn, J. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.049 · Cited by 590
PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy
Abedi-Gaballu, F., Dehghan, G., Ghaffari, M., Yekta, R., Abbaspour-Ravasjani, S., Baradaran, B., Ezzati Nazhad Dolatabadi, J., & Hamblin, M. R. (2018) · Applied Materials Today · doi:10.1016/j.apmt.2018.05.002 · Cited by 487
Harugade, A., Sherje, A. P., & Pethe, A. (2023) · Reactive and Functional Polymers · doi:10.1016/j.reactfunctpolym.2023.105634 · Cited by 474
(2020) · IntechOpen eBooks · doi:10.5772/intechopen.87879 · Cited by 384
Stimuli‐responsive nanotherapeutics for precision drug delivery and cancer therapy
Qiao, Y., Wan, J., Zhou, L., Ma, W., Yang, Y., Luo, W., Yu, Z., & Wang, H. (2019) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1527 · Cited by 332
Kim, S. (2018) · International Journal of Polymer Science · doi:10.1155/2018/1708172 · Cited by 298
Ali, E. S., Sharker, S. M., Islam, M. T., Khan, I. N., Shaw, S., Rahman, M. A., Uddin, S. J., Shill, M. C., Rehman, S., Das, N., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.011 · Cited by 267
Nanocatalyst‐Mediated Chemodynamic Tumor Therapy
Zhang, L., Li, C., Wan, S., & Zhang, X. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202101971 · Cited by 263
Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments
McQuade, R. M., Stojanovska, V., Abalo, R., Bornstein, J. C., & Nurgali, K. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00414 · Cited by 252
“Although chemotherapy has greatly improved overall survival in many types of cancer, cytotoxic side-effects are a significant hurdle greatly impeding the clinical application of otherwise beneficial therapies (Xue et al., 2011; Iwamoto, 2013).”
Durfee, P. N., Lin, Y.-S., Dunphy, D. R., Muñiz, A. J., Butler, K. S., Humphrey, K. R., Lokke, A. J., Agola, J. O., Chou, S. S., Chen, I.-M., et al. (2016) · ACS Nano · doi:10.1021/acsnano.6b02819 · Cited by 219
Xie, W., Gao, Q., Guo, Z., Wang, D., Gao, F., Wang, X., Wei, Y., & Zhao, L. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b10699 · Cited by 206
Protocells: Modular Mesoporous Silica Nanoparticle‐Supported Lipid Bilayers for Drug Delivery
Butler, K. S., Durfee, P. N., Theron, C., Ashley, C. E., Carnes, E. C., & Brinker, C. J. (2016) · Small · doi:10.1002/smll.201502119 · Cited by 186
Peptide ligand-mediated targeted drug delivery of nanomedicines
Jiang, Z., Guan, J., Qian, J., & Zhan, C. (2019) · Biomaterials Science · doi:10.1039/c8bm01340c · Cited by 172
Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges
Ubanako, P., Mirza, S., Ruff, P., & Penny, C. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1447953 · Cited by 68
PLGA-PEG-RA-based polymeric micelles for tumor targeted delivery of irinotecan
Emami, J., Maghzi, P., Hasanzadeh, F., Sadeghi, H., Mirian, M., & Rostami, M. (2018) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2017.1340950 · Cited by 36
Metadata
- Authors
- Iwamoto, T.
- Venue
- Biological and Pharmaceutical Bulletin
- Publisher
- Pharmaceutical Society of Japan
- Published
- 2013
- Volume
- 36
- Issue
- 5
- Pages
- 715-718
- ISSN
- 0918-6158 (ISSN-L)
- 1347-5215
- OpenAlex
- W2022504862
- Cited by
- 247
- References
- 0
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.